Apoptotic signaling by TNFR1 is inhibited by the α2-6 sialylation, but not α2-3 sialylation, of the TNFR1 N-glycans
The TNF-TNFR1 signaling pathway plays a pivotal role in regulating the balance between cell survival and cell death. Upon binding to TNF, plasma membrane-localized TNFR1 initiates survival signaling, whereas TNFR1 internalization promotes caspase-mediated apoptosis. We previously reported that the α2-6 sialylation of TNFR1 by the tumor-associated sialyltransferase ST6GAL1 diverts signaling toward survival by inhibiting TNFR1 internalization. In the current investigation, we interrogated the mechanisms underlying sialylation-dependent regulation of TNFR1 and uncovered a novel role for α2-6 sialylation, but not α2-3 sialylation, in mediating apoptosis-resistance. Our studies utilized HEK293 cells with deletion of sialyltransferases that modify N-glycans with either α2-3-linked sialic acids (ST3GAL3/4/6) or α2-6-linked sialic acids (ST6GAL1/2). Additionally, ST6GAL1 was re-expressed in cells with ST6GAL1/2 deletion to restore α2-6 sialylation. Using total internal reflection fluorescence (TIRF) microscopy and BS<sup>3</sup> cross-linking, we determined that, under basal conditions, cells expressing TNFR1 devoid of α2-6 sialylation displayed enhanced TNFR1 oligomerization, an event that poises cells for activation by TNF. Moreover, upon stimulation with TNF, greater internalization of TNFR1 was observed via time-lapse TIRF and flow cytometry, and this correlated with increased caspase-dependent apoptosis. These effects were reversed by ST6GAL1 re-expression. Conversely, eliminating α2-3 sialylation did not significantly alter TNFR1 clustering, internalization or apoptosis. We also evaluated the Fas receptor, given its structural similarity to TNFR1. As with TNFR1, α2-6 sialylation had a selective effect in protecting cells against Fas-mediated apoptosis. These results collectively suggest that ST6GAL1 may serve a unique function in shielding cancer cells from apoptotic stimuli within the tumor microenvironment.
Authors
- Tejeshwar C. Rao (ORCID: https://orcid.org/0000-0002-3285-1630)
- Yoshiki Narimatsu (ORCID: https://orcid.org/0000-0003-1428-5695)
- Susan L. Bellis (ORCID: https://orcid.org/0000-0002-5071-527X)
- Bingdong Sha (ORCID: https://orcid.org/0000-0002-5196-2125)
- Jihye Hwang (ORCID: https://orcid.org/0000-0001-8224-0240)
- Henrik Clausen (ORCID: https://orcid.org/0000-0002-0915-5055)
- Alexa L. Mattheyses (ORCID: https://orcid.org/0000-0002-5119-7750)
- Jiahui Tao (ORCID: https://orcid.org/0000-0002-3016-1249)
Institutions
- University of Copenhagen (DK)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Journal of Biological Chemistry
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1016/j.jbc.2024.108043
- Citations
- 7
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- National Science Foundation
- National Research Foundation
- Danmarks Grundforskningsfond
- Novo Nordisk
- National Institutes of Health
- Center for AIDS Research, University of Washington
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases